Overview

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Lurasidone Hydrochloride
Quetiapine Fumarate